• Spero Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    المصدر: Nasdaq GlobeNewswire / 07 نوفمبر 2022 07:05:00   America/Chicago

    CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Monday, November 14, 2022 at 4:30 p.m. ET to report its third quarter 2022 financial results and provide an update on its business and pipeline.

    To access the call, please dial 1-855-327-6837 (domestic) or 1-631-891-4304 (international) and refer to conference ID 10020538. The audio webcast can be accessed under "Events and Presentations" in the Investor and Media section of the Company's website at www.sperotherapeutics.com. The archived webcast will also be available on Spero's website for 30 days following the call.

    About Spero Therapeutics
    Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for bacterial infections, including multi-drug resistant bacterial infections and rare diseases.

    • Spero Therapeutics is developing SPR720 as a novel oral therapy candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections.
       
    • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain bacteria, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.
    • Spero Therapeutics also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is in development to treat multi-drug resistant Gram-negative infections in the hospital setting.

    For more information, visit https://sperotherapeutics.com.

    Investor Relations Contact: 
    Ted Jenkins
    Vice President, Investor Relations and Strategic Finance
    IR@sperotherapeutics.com
    (617) 798-4039

    Media Inquiries:
    Lora Grassilli, Health Media Relations
    Zeno Group
    lora.grassilli@zenogroup.com
    646-932-3735


    Primary Logo

شارك على،